Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Launch Plans For Lyrica Fibromyalgia Approval Include Patient Groups

Executive Summary

Pfizer's first steps in marketing Lyrica's new indication for fibromyalgia - the first FDA approval for the condition - will be partnering with patient advocacy groups to raise awareness and conduct educational programs

You may also be interested in...



Cymbalta Fibromyalgia Approval Sets Another REMS Precedent

FDA's approval of Lilly's Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation and Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides

Cymbalta Fibromyalgia Approval Sets Another REMS Precedent

FDA's approval of Lilly's Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation and Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides

Pfizer Matches Lilly In Grant Spending For 1st Quarter; Fibromyalgia Is Focus

Pfizer and Lilly dispensed comparable amounts in grants during the first quarter of 2008, as revealed by Pfizer's inaugural online posting of gifts and charitable donations, unveiled May 15

Related Content

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel